{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:55:17Z","timestamp":1792112117652,"version":"4.4.0"},"reference-count":27,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2004,10,12]],"date-time":"2004-10-12T00:00:00Z","timestamp":1097539200000},"content-version":"vor","delay-in-days":3937,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1994,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Certain aminotetralins are known to be potent dopamine D<jats:sub>2<\/jats:sub> receptor agonists. N\u20100923, [\u2010]2\u2010(N\u2010propyl\u2010N\u20102\u2010thienylethylamino)\u20105\u2010hydroxytetralin HCl, recognizes the high and low affinity states of the D<jats:sub>2<\/jats:sub> receptor in membranes from bovine caudate with a K<jats:sub>low<\/jats:sub> of 79 nM. The selectivity ratio is D<jats:sub>2<\/jats:sub>\/D<jats:sub>1<\/jats:sub> = 15 and D<jats:sub>2<\/jats:sub>\/\u03b1<jats:sub>2<\/jats:sub> = 1.4. N\u20100923 also inhibits dopamine uptake and prolactin secretion, and it is an antagonist at the \u03b1<jats:sub>2<\/jats:sub> receptor. N\u20100923 (3\u2013300 nmol\/kg, s.c.) induced dose\u2010dependent contralateral turning behavior in rats with unilateral 6\u2010hydroxydopamine lesions of the substantia nigra. The ED<jats:sub>50<\/jats:sub> of 30 nmol\/kg was effective for 1 h. The positive enantiomer (N\u20100924; 300 nmol\/kg, s. c.) was without effect. A hemiparkinsonian syndrome was induced in four <jats:italic>Macaca nemestrina<\/jats:italic> monkeys by unilateral infusion of the neurotoxin MPTP into the right carotid artery. Video recordings of free\u2010moving behavior revealed bradykinesia, disuse of the contralateral upper limb and turning in a direction ipsilateral to the lesion. N\u20100923 (3\u2013300 nmol\/kg, i.m.) induced contralateral turning behavior, exploratory activity, and contralateral limb usage. The ED<jats:sub>50<\/jats:sub> for turning (30 nmol\/kg) was effective for 0.5 h. The potency order for induction of contralateral rotations was (+)\u2010PHNON\u20100923 &gt; bromocriptine. N\u20100924 (300 nmol\/kg, i. m.) was ineffective. We conclude that N\u20100923 may be useful as a therapeutic agent in the treatment of Parkinson's disease.<\/jats:p>","DOI":"10.1002\/mds.870090204","type":"journal-article","created":{"date-parts":[[2004,12,31]],"date-time":"2004-12-31T11:35:19Z","timestamp":1104492919000},"page":"147-154","source":"Crossref","is-referenced-by-count":59,"title":["N\u20100923, a selective dopamine D<sub>2<\/sub> receptor agonist, is efficacious in rat and monkey models of Parkinson's disease"],"prefix":"10.1002","volume":"9","author":[{"given":"J. D.","family":"Belluzzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. F.","family":"Domino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. M.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. S.","family":"Bankiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. A.","family":"McAfee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,10,12]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198604000-00004"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198604000-00007"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90644-7"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(86)90037-3"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(89)90348-8"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1988.tb01830.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0022-3565(25)21644-5","article-title":"Pharmacologic profile of a novel potent direct\u2010acting dopamine agonist, (+)\u20104\u2010propyl\u20109\u2010hydroxynaphthoxazine [(+)\u2010PHNO]","volume":"230","author":"Martin GE","year":"1984","journal-title":"J Pharmacol Exp Therap"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00168809"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.10.1541"},{"key":"e_1_2_1_11_2","first-page":"112","volume-title":"Proceedings of the International Sardinian Symposium, MPTP\u2010Sardinia '88, Degeneration and Regeneration in CNS","author":"McAfee DA","year":"1988"},{"key":"e_1_2_1_12_2","first-page":"1110","article-title":"N\u20100923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's","volume":"16","author":"Belluzzi JD","year":"1990","journal-title":"Soc Neurosci Abst"},{"key":"e_1_2_1_13_2","unstructured":"The guide for the care and use of laboratory animals. Rev. ed. DHEW Publication no. (NIH) 86\u201023 Washington DC: Superintendent of Documents 1985."},{"key":"e_1_2_1_14_2","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0026-895X(25)14176-X","article-title":"Dopamine D2 receptor binding sites for agonists: a tetrahedral model","volume":"28","author":"Seeman P","year":"1985","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(80)90515-1"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00717737"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(70)90187-3"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(86)90431-5"},{"key":"e_1_2_1_19_2","volume-title":"The anatomy of the rhesus monkey (Macaca mulatta)","author":"Hartman CG","year":"1933"},{"key":"e_1_2_1_20_2","first-page":"1","volume-title":"An atlas and dissection manual of rhesus monkey anatomy","author":"Berringer OM","year":"1968"},{"key":"e_1_2_1_21_2","volume-title":"The rhesus monkey. Vol. 1: anatomy and physiology","author":"Bourne GH","year":"1975"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S0026-895X(25)15078-5","article-title":"The ternary complex model its properties and applications to ligand interactions with the D2 dopamine receptor of the anterior pituitary gland","volume":"26","author":"Wreggett KA","year":"1985","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_23_2","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1016\/S0021-9258(20)65148-1","article-title":"Anterior pituitary dopamine receptors demonstration of intercovertible high and low affinity states of the D2 dopamine receptor","volume":"257","author":"Sibley DR","year":"1982","journal-title":"J Biol Chem"},{"key":"e_1_2_1_24_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0026-895X(25)13494-9","article-title":"Characterization of dopamine receptors mediating inhibition of adenylate cyclase activity in the rat striatum","volume":"28","author":"Onali P","year":"1985","journal-title":"Mol Pharmacol"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","unstructured":"MartinPL KellyM CusackNJ. N\u20100923 a selective D2\u2010dopamine receptor agonist demonstrates the presence of D2\u2010dopamine receptors in the mouse vas deferens.J Pharmacol Expt Ther1993(in press).","DOI":"10.1016\/S0022-3565(25)39427-9"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0022-3565(25)11334-7","article-title":"Complex prejunctional actions of the D2 dopamine agonists N\u20100923 and N\u20100924 in the rat tail artery","volume":"260","author":"Friedman DF","year":"1992","journal-title":"J Phamacol Exp Ther"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0022-3565(25)21227-7","article-title":"Selectivity of (+)\u20104\u2010propyl\u20109\u2010hydroxynaphthoxazine [(+)\u2010PHNO] for dopamine receptors in vitro and in vivo","volume":"233","author":"Martin GE","year":"1985","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_28_2","first-page":"469","volume-title":"Handbook of Parkinson's disease","author":"LeWitt PA","year":"1992"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870090204","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870090204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:23:27Z","timestamp":1760970207000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870090204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1994,1]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1994,1]]}},"alternative-id":["10.1002\/mds.870090204"],"URL":"https:\/\/doi.org\/10.1002\/mds.870090204","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[1994,1]]}}}